DUBLIN–(BUSINESS WIRE)–The report “Diabetic Retinopathy Market by Type (Proliferative Diabetic Retinopathy, Diabetic Macular Edema) and Treatment Type: Global Opportunity Analysis and Industry Forecast, 2020-2030” has been added to from ResearchAndMarkets.com offer.

Global Diabetic Retinopathy Market was valued at USD 3,086.00 Million in 2020 and is projected to reach USD 10,785.50 Million by 2030, registering a CAGR of 13.7% from 2021 to 2030.

Diabetic retinopathy is damage to the blood vessels of the retina that occurs as a result of diabetes. Diabetic retinopathy can cause a range of symptoms, including blurred vision, difficulty seeing colors, and eye floaters. Left untreated, it can lead to vision loss. Diabetic retinopathy is the leading cause of new cases of blindness in adults, as well as the most common cause of vision loss in people with diabetes. People may not have any early symptoms of diabetic retinopathy.

The diabetic retinopathy market has witnessed phenomenal growth due to technological advancements in ophthalmic surgical and diagnostic instruments. Additionally, optical coherence tomography and other technologically improved devices used in diagnosis provide superior cross-sectional images that allow the physician to make better decisions. Additionally, the surgical instruments have increased precision which improves the success rates of the surgery.

Thus, the availability of these improved ophthalmic devices and instruments has facilitated the diagnostic and surgical procedures which positively impact the growth of the industry. However, the complications and adverse effects associated with medications prescribed to minimize the impact of diabetic retinopathy may hamper the growth of the industry to some extent.

Increasing geriatric populations, increasing attention and awareness of early diagnosis to control disease growth, increasing prevalence of diabetes, and increasing incidence of blindness due to Diabetes Drive Market Growth. However, this growth is limited by the shortage of qualified ophthalmologists and the long time for drug approvals.

Conversely, the emergence of combination therapies for the treatment of diabetic macular edema and the emerging Asia-Pacific and LAMEA markets are expected to provide several opportunities for market growth over the forecast period.

Regionally, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America led the market in 2020, owing to the high prevalence of DR in this region coupled with well-established infrastructure and growing government initiatives to create awareness that would help people get screened of the DR.

However, Asia-Pacific is expected to experience tremendous market growth over the forecast period, owing to high population, high disposable income, and improving patient awareness of diabetic retinopathy treatment.

Main results of the study

  • By type, the proliferative diabetic retinopathy segment is currently dominating the global diabetic retinopathy market and is expected to continue during the forecast period due to the increasing prevalence of the disease globally. Globally, in 2017, among adults aged 45 and over with diagnosed diabetes, 32.2% had cataracts, 8.6% had diabetic retinopathy, 7.1% had glaucoma and 4. 3% suffered from macular degeneration. their market share

  • By type of treatment, laser surgeries segment dominated the global diabetic retinopathy market in 2020 and is expected to dominate the market. Since this type of treatment has been available in the market for a long time, there is great acceptance and familiarity with the procedure. Thus, laser surgeries are the lucrative investment pocket

  • Based on region, in 2020, North America led the market in 2020, owing to the high prevalence of R&D in this region coupled with well-established infrastructure and growing government initiatives to raise awareness people who would help people get screened for DR However, Asia-Pacific is expected to witness considerable growth in the diabetic retinopathy market over the forecast period, owing to high population, high disposable income and improving patient awareness of the treatment of diabetic retinopathy.

Key players operating in the global diabetic retinopathy market are

  • Alimera Science, Inc.

  • Abbvie, Inc.

  • Ampio Pharmaceuticals, Inc.

  • Bayer AG

  • Kowa Co.,Ltd

  • Novartis

  • Pfizer, Inc.

  • Regeneron Pharmaceuticals, Inc.

  • F-Hoffmann-La Roche SA

  • Valeant Pharmaceuticals International, Inc (Bausch Health Companies Inc)

KEY MARKET SEGMENTS

By type

  • Proliferative diabetic retinopathy

  • Diabetic macular edema (DME)

By type of treatment

  • Anti-VEGF drug

  • Steroid implants

  • Laser surgeries

  • Vitrectomy

By region

  • North America

  • WE

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • The rest of Europe

  • Asia Pacific

  • Japan

  • China

  • Australia

  • India

  • South Korea

  • Rest of Asia-Pacific

  • LAMEA

  • Brazil

  • Saudi Arabia

  • South Africa

  • Rest of LAMEA

For more information about this report visit https://www.researchandmarkets.com/r/eh6ws6